CONMED (CNMD) Projected to Post Earnings on Wednesday

CONMED (NYSE:CNMD - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect CONMED to post earnings of $0.81 per share and revenue of $313.38 million for the quarter. CONMED has set its FY 2025 guidance at 4.250-4.400 EPS.

CONMED (NYSE:CNMD - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Price Performance

NYSE:CNMD traded up $0.23 during trading hours on Monday, hitting $50.94. 765,569 shares of the company's stock traded hands, compared to its average volume of 450,158. The business's fifty day simple moving average is $56.75 and its two-hundred day simple moving average is $65.09. CONMED has a 52 week low of $46.00 and a 52 week high of $78.58. The company has a quick ratio of 1.06, a current ratio of 2.30 and a debt-to-equity ratio of 0.94. The firm has a market cap of $1.58 billion, a P/E ratio of 12.01, a P/E/G ratio of 1.83 and a beta of 1.28.

CONMED Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were paid a dividend of $0.20 per share. The ex-dividend date was Friday, March 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.57%. CONMED's dividend payout ratio (DPR) is presently 18.87%.

Analyst Upgrades and Downgrades

CNMD has been the topic of several analyst reports. Stifel Nicolaus cut CONMED from a "buy" rating to a "hold" rating and lowered their price objective for the company from $75.00 to $55.00 in a research report on Monday. Needham & Company LLC lowered their target price on CONMED from $97.00 to $91.00 and set a "buy" rating for the company in a research report on Thursday, February 6th. Wells Fargo & Company cut their price target on shares of CONMED from $74.00 to $70.00 and set an "equal weight" rating on the stock in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. cut CONMED from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $85.00 to $70.00 in a research note on Thursday, February 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $73.20.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.